Article

Individual and dyadic barriers to a pharmacotherapeutic treatment of hypoactive sexual desire disorders: results and implications from a small-scale study with bupropion.

Department of Clinical Psychology, Hannover Medical School, Hannover, Germany.
Journal of Sex and Marital Therapy (Impact Factor: 1.27). 07/2012; 38(4):325-48. DOI: 10.1080/0092623X.2011.606495
Source: PubMed

ABSTRACT This article describes the results of an independent small-scale trial with the centrally acting agent bupropion for female hypoactive sexual desire disorder. The main goals were to gain insight into the intrapsychic and interpersonal barriers to improvement associated with the pharmacological treatment of this common disorder. Eligible subjects entered a 2-week run-in period and a 4-week placebo phase, followed by a 20-week treatment phase. In addition to semi-structured clinical interviews and a set of standardized questionnaires, we used 2 self-developed questionnaires, addressing the period between visits and the week preceding each visit. Participants were 16 women who entered the placebo phase and 10 who completed the medication period. Analyses of pre-post scores and of the questionnaire addressing the time between visits yielded no significant changes. The questionnaire focusing on the week preceding each visit indicated improvements in sexual desire, arousability, and orgasmic ease after Week 8. In the clinical interviews, half of the women reported subjective improvements of sexual desire and arousability that could not be transferred to the sexual relationship as a result of individual and dyadic barriers. Overall, a centrally acting agent such as bupropion may be a viable option for female sexual dysfunction, but it seems mandatory to embed it in a psychotherapeutic approach.

1 Follower
 · 
81 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Resumo: A função sexual representa um componente importante da saúde e da qualidade de vida. O objetivo deste artigo foi descrever aspectos normais e patológicos da função sexual feminina e expor os métodos diagnósticos e terapêuticos, abordando a prevalência no Brasil. Para isso, foi realizada uma revisão da literatura, de artigos publicados entre 1985 e 2012, dos quais foram selecionados 56, indexados no PubMed/Medline e SciELO. Os achados indicam que as disfunções sexuais nas mulheres apresentam etiologia multifatorial e são pouco estudadas na população brasileira. A terapêutica deve ser adaptada de acordo com a necessidade da paciente e desenvolvida por uma equipe multidisciplinar. Abstract: Sexual function represents an important component of health and quality of life. The purpose of this article was to describe normal and pathological aspects of female sexual function and expose the diagnostic and therapeutic methods, addressing the prevalence in Brazil. For this, was realized a literature review, of articles published from 1985 to 2012, which 56 were selected, indexed in PubMed/Medline and SciELO. The findings indicate that female sexual dysfunctions have multifactorial etiology and are not very well studied in the Brazilian population. Therapy should be tailored according to the needs of the patient and done by a multidisciplinary team.
    Femina: revista da Federação Brasileira das Sociedades de Ginecologia e Obstetrícia 01/2012; 40(4):195-202.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Evaluation of: Burri A, Corina G, Myriam L, Timothy S, Qazi R. A multivariate twin study of female sexual dysfunction. J. Sex. Med. 9, 2671-2681 (2012). This study highlights the complicated nature of female sexual dysfunction (FSD), demonstrating both genetic and environmental factors involved in its etiology. The authors gathered the Female Sexual Function Index scores in a twin population, and examined which dimensions of FSD may be genetically determined or environmentally shared. The results indicate that approximately one-third of the covariance between FSD dimensions was genetic, with one identified loci influencing all phases of the sexual response cycle, whereas the other loci influenced only arousal and orgasm function. They also show that specific types of sexual problems may be related more to nonshared environmental factors. Overall, the results suggest FSD is multifactorial.
    Women s Health 03/2013; 9(2):135-7. DOI:10.2217/whe.13.6
  • [Show abstract] [Hide abstract]
    ABSTRACT: Antidepressant-induced sexual dysfunction adversely affects the quality of life of antidepressant users and reduces compliance with treatment. Animal models provide an instructive approach for examining potential sexual side effects of novel drugs. This review discusses the stability and reproducability of our standardized test procedure that assesses the acute, subchronic and chronic effects of psychoactive compounds in a 30minute mating test. In addition, we present an overview of the effects of several different (putative) antidepressants on male rat sexual behavior, as tested in our standardized test procedure. By comparing the effects of these mechanistically distinct antidepressants (paroxetine, venlafaxine, bupropion, buspirone, DOV 216,303 and S32006), this review discusses the putative mechanism underlying sexual side effects of antidepressants and their normalisation. This review shows that sexual behavior is mainly inhibited by antidepressants that increase serotonin neurotransmission via blockade of serotonin transporters, while those that mainly increase levels of dopamine and noradrenaline are devoid of sexual side effects. Those sexual disturbances can not be normalized by simultaneously increasing noradrenaline neurotransmission, but are normalized by increasing both noradrenaline and dopamine neurotransmission. Therefore, it is hypothesized that the sexual side effects of selective serotonin reuptake inhibitors may be mediated by their inhibitory effects on dopamine signalling in sex brain circuits. Clinical development of novel antidepressants should therefore focus on compunds that simultaneously increase both serotonin and dopamine signalling.
    Pharmacology Biochemistry and Behavior 10/2013; DOI:10.1016/j.pbb.2013.10.004 · 2.82 Impact Factor